Intra-Cellular Therapies, Inc.
Methods of treating bipolar disorder
Last updated:
Abstract:
The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
Status:
Grant
Type:
Utility
Filling date:
10 Jul 2019
Issue date:
8 Jun 2021